Latest News-Henlius Mediaroom_Page

Henlius Forecasts Profit in 1H 2023

Spurring a Seamless R&D, Manufacturing, and Commercialisation Positive Cycle SHANGHAI, July 3, 2023...

2023-07-03 17:49 2184

Henlius Achieved Steep Revenue Growth in Q1 2023, Core Products Sales Surged

SHANGHAI, April 17, 2023 /PRNewswire/ -- As a global innovative biopharmaceutical company, Henlius ...

2023-04-17 07:45 2038

Henlius 2022 Annual Results: Significant Achievements in Commercialisation, Surged to RMB3.2 Billion in Revenues

SHANGHAI, April 1, 2023 /PRNewswire/ -- Henlius (2696.HK) announced its 2022 annual results. In 202...

2023-04-01 00:06 8745

EMA Validates Marketing Authorization Application for Henlius' HANSIZHUANG (Serplulimab)

* HANSIZHUANG (serplulimab) is the first anti-PD-1 mAb for the first-line treatment of small cell...

2023-03-24 08:00 2298

Henlius Announces U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar Trastuzumab HLX02

* The first Chinese biosimilar approved in both China and the EU, and potentially to be approved ...

2023-02-15 16:49 2732

Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC

* World's first anti-PD-1 mAb for the first-line treatment of SCLC * Making a new record with th...

2023-01-17 19:42 2433

First Patient dosed in a Head-to-Head First-Line Bridging Study of HANSIZHUANG for ES-SCLC treatment in the US

SHANGHAI, Nov. 30, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the...

2022-11-30 08:00 2610

Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Receives NMPA Approval for the Treatment of sqNSCLC

SHANGHAI, Nov. 1, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696. HK) announced that its...

2022-11-01 21:32 3001

ASTRUM-005: The first immunotherapy clinical study of SCLC published in JAMA, one of the top medical journals in the world

* ASTRUM-005 is the first study to demonstrate that PD-1 inhibitors plus chemotherapy can improve...

2022-09-28 21:00 1810

Henlius 2022 H1 Results: Sharpen all-round edges, advance in evolution to Biopharma

SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- Henlius (2696.HK) announced its 2022 interim results. As a ...

2022-08-18 21:35 2744

Henlius HANQUYOU Received TGA Approval in Australia

SHANGHAI, July 26, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the...

2022-07-26 18:03 2644

Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies

* Palleon and Henlius to co-develop Bifunctional HER2-Sialidase and a second bifunctional sialida...

2022-06-28 21:50 2572

ASTRUM-005: Henlius Released Phase 3 Study Results for the First-line Treatment of Small Cell Lung Cancer of Serplulimab at ASCO 2022

SHANGHAI, June 6, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that an ...

2022-06-06 21:00 2111

ASTRUM-005: Henlius Released Phase 3 Study Results for the First-line Treatment of Small Cell Lung Cancer of Serplulimab at ASCO 2022

The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for the First-Line Treatment of Small Cell Lung Cancer Accepted by NMPA

SHANGHAI, April 11, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that th...

2022-04-11 22:07 1409

Henlius' Serplulimab Granted Orphan-Drug Designation in the United States for Small Cell Lung Cancer

SHANGHAI, April 7, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the...

2022-04-07 22:21 2750

Henlius Receives NMPA Approval for its First Innovative Monoclonal Antibody HANSIZHUANG

SHANGHAI, March 25, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that it...

2022-03-25 21:24 4916

Henlius 2021 Annual Results: New Record in Performance, Evolving to Biopharma

SHANGHAI, March 17, 2022 /PRNewswire/ -- Henlius (2696.HK) announced its annual results for the yea...

2022-03-17 08:00 3002

Henlius 2021 Annual Results: New Record in Performance, Evolving to Biopharma

SHANGHAI, March 16, 2022 /PRNewswire/ -- Henlius (2696.HK) announced its annual results for the yea...

2022-03-16 23:46 1821

Henlius' anti-PD-1 mAb MRCT achieved 15.38 months OS in first-line treatment of SCLC, reducing the risk of death by 38% of the overall population

* The ASTRUM-005 states that serplulimab combined with carboplatin-etoposide prolonged median OS ...

2021-12-20 22:00 2264

Henlius' Phase 3 clinical study of novel PD-1 inhibitor serplulimab for the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC) meets primary study endpoint

SHANGHAI, Dec. 8, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the ...

2021-12-08 08:30 2581